44 results about "Cholanic acid" patented technology

The invention relates to the field of biological catalysis, and discloses a method and a device for generating ursodesoxycholic acid through continuous flow catalysis of chenodeoxycholic acid. Comprising the following steps: (1) in the presence of first immobilized cells, carrying out a first catalytic reaction on a reaction system containing chenodeoxycholic acid to obtain a first product, the first immobilized cells expressing 7 alpha-hydroxysteroid dehydrogenase and lactic dehydrogenase; the concentration of the chenodeoxycholic acid in the reaction system is 40 to 70 mM; (2) adjusting the pH value of the first product to 8-9, and then in the presence of a second immobilized cell, carrying out a second catalytic reaction on the first product after the pH value is adjusted to obtain ursodesoxycholic acid, and the second immobilized cell expresses 7 beta-hydroxysteroid dehydrogenase and glucose dehydrogenase. According to the method, the stable activity of a catalytic system is kept, efficient conversion of high-concentration CDCA is achieved, meanwhile, precipitation of 7-KLCA is thoroughly avoided, and the synthesis efficiency, the product purity and the process continuity of UDCA are remarkably improved.

The invention provides a composition containing bile acid and bifidobacterium animalis subsp. Lactis for improving tear stains of dogs and cats. The composition is prepared from the bile acid and the bifidobacterium animalis subsp. Lactis ZYhyy-017, and the composition is prepared from the bile acid, the bifidobacterium animalis subsp. Lactis ZYhyy-017, the bifidobacterium animalis subsp. Lactis ZYhyy-017 and the bifidobacterium animalis subsp. Lactis ZYhyy-017. The bifidobacterium animalis subsp. Lactis ZYhyy-017 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.37292, and the preservation date is January 6, 2026. The bifidobacterium animalis subsp. Lactis ZYhyy-017 is preserved in the China General Microbiological Culture Collection Center (CGMCC). The bile acid is chenodeoxycholic acid (CDCA). The composition regulates and controls a bile acid-porphyrin metabolic pathway in a targeted manner through the synergistic effect of bile acid and bifidobacterium animalis subsp. Lactis ZYhyy-017, porphyrin metabolism in pets is regulated from the source, intestinal and liver axis metabolism and liver functions are optimized, long-acting and safe improvement of tear stains of dogs and cats is achieved, and the composition has a wide application prospect. Meanwhile, the technical blank that bile acid and specific probiotics are synergistically applied to the field of tear stain improvement of dogs and cats is filled up, and the actual requirement for tear stain root improvement in pet feeding is met.

The invention discloses a synthesis method of N-goose deoxycholyl-L-aspartic acid and application of the N-goose deoxycholyl-L-aspartic acid in preparation of a medicine for improving metabolism-related fatty liver diseases. According to the method provided by the invention, chenodeoxycholic acid and L-dimethyl aspartate hydrochloride are taken as raw materials, and a chenodeoxycholic acid-dimethyl aspartate intermediate is synthesized, so that a target compound-N-chenodeoxycholyl-L-aspartic acid with a brand new structure is efficiently prepared. The compound shows a treatment effect superior to that of obeticholic acid (OCA) in an animal model, and can effectively improve multiple indexes such as fatty degeneration, inflammation and fibrosis of the liver. The invention provides a brand new solution for major clinical challenges of insufficient curative effect, large side effect, drug withdrawal rebound and the like of the current MAFLD treatment drug, and provides a candidate compound with a wide prospect for developing a novel efficient MAFLD treatment drug.

This invention provides a 7β-HSDH enzyme mutant, its encoding gene, and its applications. Through artificial mutation screening, 7α-HSDH and 7β-HSDH enzyme mutants with specific amino acid sequences were identified, resulting in improved enzyme activity and catalytic efficiency compared to wild-type 7α-HSDH and wild-type 7β-HSDH. This invention also provides a method for preparing ursodeoxycholic acid using the aforementioned 7α-HSDH and 7β-HSDH enzyme mutants, specifically using NADP... + A one-pot catalytic method for the conversion of chenodeoxycholic acid to ursodeoxycholic acid using NADPH-dependent 7α-HSDH enzyme mutants and NADPH-dependent 7β-HSDH enzyme mutants is employed. This method is simple, yields high product conversion, and can also achieve the conversion of the coenzyme NADP. + / NADPH's self-circulating regeneration eliminates the need for auxiliary enzymes and raw materials used in coenzyme regeneration, greatly reducing production costs and environmental pressure, and possessing enormous potential for industrial applications.

The invention provides an impurity removal method of a chenodeoxycholic acid crude product, which comprises the following steps: dissolving the chenodeoxycholic acid crude product and glucose in a solvent, adding alkali to control the pH value of the system to be 8-10, and adding thiourea to react so as to convert 22-ene-chenodeoxycholic acid impurities into chenodeoxycholic acid. According to the impurity removal method provided by the invention, the 22-ene-chenodeoxycholic acid impurity in chenodeoxycholic acid can be effectively removed without adopting a heavy metal catalyst and the like, and the method is convenient to operate, mild in condition, low in production risk and suitable for large-scale industrial production.

The present application relates to the application of Hhex agonists in promoting anti-tumor immunity. Specifically, the present application provides a pharmaceutical composition comprising chenodeoxycholic acid and an anti-PD-1 antibody. The present application also provides the use of chenodeoxycholic acid and an anti-PD-1 antibody in the preparation of a drug for promoting anti-tumor immunity. In addition, the present application also provides the use of chenodeoxycholic acid and an anti-PD-1 antibody in the preparation of a drug for treating tumors. The present application uses chenodeoxycholic acid to improve the tumor immune microenvironment and uses it to treat subcutaneous tumors, further verifying that the application of chenodeoxycholic acid can improve the tumor immune microenvironment.

This disclosure relates to hyaluronic acid nanoparticles containing an anticancer agent such as a NADPH oxidase (NOX) inhibitor for targeted delivery to cancerous cells or tumors. In certain embodiments, the nanoparticles are made up of hyaluronic acid conjugated to hydrophobic moieties. In certain embodiments, the hydrophobic moieties are steroid based compounds, such as 5beta-cholanic acid.

The invention relates to the technical field of aquaculture feed, in particular to a feed additive for improving ovary color of scylla paramamosain and application of the feed additive. The feed additive is prepared from the following raw material components in parts by mass: 30-60 parts of Chinese wolfberry fruit powder, 10-30 parts of a marigold extract, 2-8 parts of chenodeoxycholic acid and 5-15 parts of vitamin E powder. The additive systematically solves the technical bottlenecks of low absorptivity and unstable deposition of natural pigments in crab bodies through the synergistic effect of all the components. When the feed additive is added into feed for fattening female scylla paramamosain, the ovary redness value can be remarkably increased, the color is rich and natural, and meanwhile, the growth of parent crabs and the development of gonad are promoted. The feed is completely prepared from natural raw materials, is safe, free of residues and controllable in cost, and provides an effective scheme for realizing high-valued and green cultivation of scylla paramamosain'red cream crab '.

The invention belongs to the technical field of fish and shrimp breeding feed additives, and particularly relates to a bile acid composition for fish and shrimp feed and a preparation method of the bile acid composition, and the composition comprises the following components in parts by weight: 50-60 parts of hyocholic acid, 40-55 parts of chenodeoxycholic acid, 40-60 parts of hyodeoxycholic acid, 30-45 parts of methionine glycine dipeptide and 60-115 parts of a compound plant extract. According to the invention, the methionine glycine dipeptide is used for improving the lipid metabolism capability of fishes and shrimps; the composite plant extract is used for enhancing the immunity and the anti-stress capability of the fish and the shrimps.

The application discloses a synthesis method of N-chenodeoxycholyl-L-aspartic acid and application of the N-chenodeoxycholyl-L-aspartic acid in preparation of a medicine for improving metabolic associated fatty liver disease. The method provided by the application uses chenodeoxycholic acid and L-aspartic acid dimethyl ester hydrochloride as raw materials, synthesizes a chenodeoxycholic acid-aspartic acid dimethyl ester intermediate, and efficiently prepares a target compound, N-chenodeoxycholyl-L-aspartic acid, which is a novel structure, the compound exhibits a treatment effect superior to that of obeticholic acid (OCA) in an animal model, and can effectively improve multiple indexes such as liver steatosis, inflammation and fibrosis. The application provides a novel solution for major clinical challenges such as insufficient treatment effect, large side effect and rebound after drug withdrawal of current MAFLD treatment medicines, and provides a candidate compound with broad prospects for developing a new high-efficiency MAFLD treatment medicine.

This invention relates to the field of traditional Chinese medicine technology, specifically to a composition for clearing heat and detoxifying, protecting the liver and improving eyesight, its pharmaceutical preparation and application. The raw materials of the composition, by weight, include the following components: 10-30 parts ursodeoxycholic acid, 1-5 parts chenodeoxycholic acid, 5-15 parts Lycium barbarum polysaccharide, 5-18 parts betaine, 1-5 parts glycyrrhizic acid, 0.2-5 parts glycyrrhetinic acid, and 1-5 parts glycyrrhizin. This invention combines these components to achieve the effects of clearing heat and detoxifying, protecting the liver and improving eyesight. Pharmacological experiments have demonstrated that it has significant antipyretic effects, prevents and treats eye fatigue, and improves acute liver injury.

The application discloses a chemical synthesis method of 7-ketolithocholic acid (3alpha-hydroxy-7-keto-5beta-cholestane-24-oic acid), and belongs to the field of organic chemical synthesis. The 7-ketolithocholic acid is synthesized from a plant source compound BA through steps of glycol or neopentyl glycol protection, oxidation, Wittig reaction, deprotection, reduction and hydrolysis. The raw material used for synthesizing the 7-ketolithocholic acid is cheap and easy to obtain, the synthesis steps are simple and convenient to operate, the yield is high, the environment is friendly, and the industrialized production is facilitated.

This invention discloses an evaluation method for bile acids in alleviating intestinal inflammation in grouper, belonging to the field of aquaculture technology. Addressing the intestinal inflammation problem caused by feed oxidation, pathogen infection, or water quality deterioration in intensive grouper farming, this invention proposes to achieve efficient regulation of intestinal health by adding a compound bile acid composition to the feed. The core technical solution of the method is as follows: a compound bile acid is formed by compounding porcine deoxycholic acid, chenodeoxycholic acid, and porcine cholic acid in a specific ratio, combined with a carrier premixing process to prepare a bile acid premix, which is then added to the basal feed at 0.15%-0.60% of the total feed mass. This invention effectively alleviates enteritis symptoms in grouper by enhancing the integrity of the intestinal epithelial structure, repairing damaged mucosal barriers, regulating inflammatory responses, and optimizing intestinal flora composition. It provides a safe and efficient technical solution for replacing feed antibiotics in aquaculture, with significant economic and ecological benefits.

The invention discloses a silanization purification method for ursodesoxycholic acid prepared by a biological enzyme method, and belongs to the field of biological pharmacy. According to the method, the whole-cell reaction liquid is used as a purification object, insoluble macromolecular impurities are removed through preliminary impurity removal and high-concentration acetone-water dissolution, the target content of UDCA is 80% or above successfully, and the product is pure white; the method comprises the following steps: carrying out a reaction on a UDCA silanization derivative and-OH by using a silanization reagent, separating the UDCA silanization derivative from other silanization derivatives, and hydrolyzing the UDCA silanization derivative to realize purification of UDCA. The content of CDCA in the final product is effectively controlled to be 0.5% or below, the purity of the UDCA crude product is improved from 53% to 98.5% or above, and the requirements of UDCA bulk drugs are met. The method is simple in process and low in cost, the obtained product is high in purity, the chenodeoxycholic acid impurity content is low, and the chenodeoxycholic acid can be used as a raw material of a pharmaceutical preparation.

The invention discloses a ruminococcus torsionosus-sourced 7beta-HSDH enzyme mutant and application thereof, the ruminococcus torsionosus-sourced 7beta-HSDH enzyme is taken as a research object, a series of single-point mutation and combined mutation of the 7beta-HSDH enzyme are provided, and compared with wild type 7beta-HSDH enzyme, the thermal stability of the 7beta-HSDH enzyme mutant is improved by 1-20 DEG C, and the 7beta-HSDH enzyme mutant has the advantages that the 7beta-HSDH enzyme mutant has the advantages that the 7beta-HSDH enzyme mutant can be used for preparing the 7beta-HSDH enzyme mutant; compared with a wild type 7beta-HSDH enzyme, the 7 beta-HSDH enzyme has the advantages that the Tm value of the (C217I and E252K) mutant is improved by 1.2-4.2 times, the enzyme activity of the (C217I and E252K) mutant is 4.2 times that of the wild type 7beta-HSDH enzyme, and the (T103I, D251K, L229K and S161A) mutant has ultrahigh heat stability, the Tm value is close to 68 DEG C, and 50% of enzyme activity is maintained, so that the 7 beta-HSDH enzyme can be used for preparing the 7 beta-HSDH enzyme. Compared with a wild type 7 beta-HSDH enzyme, the 7 beta-HSDH enzyme mutant provided by the invention has wider application conditions, is more suitable for efficiently producing ursodesoxycholic acid from 3 alpha-hydroxy-7-oxo-5beta-cholanic acid (7-ketolithocholic acid, 7-KLCA) by a biological conversion method, and is beneficial to large-scale production and industrial application.

The present invention relates to the field of medicinal chemistry. Specifically disclosed is a use of oxime-based cholic acid (CA) analogs as allosteric agonists for TGR5. In the present invention, CA used as a raw material undergoes a series of reactions to obtain CA intermediates each having an oxime at either or both of positions 7 and 12, and a series of modifications are then carried out on positions 24 and the oximes of these intermediates to obtain CA analogs as represented by formula 1, formula 2, or formula 3. The present invention uses a GloSensor cAMP accumulation assay to test the functional activity and allosteric mechanism of all target compounds on TGR5. Pharmacological results have shown that all synthesized target compounds have relatively good agonistic activity on TGR5 and can positively allosterically regulate the functional activity of chenodeoxycholic acid (CDCA) or lithocholic acid (LCA), that is, the target compounds are all positive allosteric modulators or allosteric agonists for TGR5.

The application belongs to the field of new adjuvants and new dosage forms of pharmaceutical preparations, and particularly relates to a type I and type II immunogenic cell death inducer ion pairing engineered nanoassemblies as well as construction and application thereof. The nanoassemblies are composed of type I ICD inducers, type II ICD inducers, hydrophobic auxiliary counterions and amphiphilic lipid ion pairing. The type I ICD inducer is selected from mitoxantrone, doxorubicin, oxaliplatin or cyclophosphamide; the type II ICD inducer is selected from hypericin; and the hydrophobic auxiliary counterion is selected from cholesteryl sodium sulfate, cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, glycolcholic acid, taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, deoxycholic acid lysine derivative, oleanolic acid and ursolic acid. The type I and type II ICD inducers are combined in the application, and have a synergistic tumor treatment effect.

This invention provides a 7α-HSDH enzyme mutant and a 7β-HSDH enzyme mutant, their encoding genes, and their applications. Through artificial mutation screening, 7α-HSDH and 7β-HSDH enzyme mutants with specific amino acid sequences were identified, resulting in improved enzyme activity and catalytic efficiency compared to wild-type 7α-HSDH and wild-type 7β-HSDH. This invention also provides a method for preparing ursodeoxycholic acid using the aforementioned 7α-HSDH and 7β-HSDH enzyme mutants, specifically using NADP... + A one-pot catalytic method for the conversion of chenodeoxycholic acid to ursodeoxycholic acid using NADPH-dependent 7α-HSDH enzyme mutants and NADPH-dependent 7β-HSDH enzyme mutants is employed. This method is simple, yields high product conversion, and can also achieve the conversion of the coenzyme NADP. + / NADPH's self-circulating regeneration eliminates the need for auxiliary enzymes and raw materials used in coenzyme regeneration, greatly reducing production costs and environmental pressure, and possessing enormous potential for industrial applications.

The application discloses a preparation method of chenodeoxycholic acid. The method uses 22E-3alpha-acyloxy-7-ketone-cholest-5,22-diene-24-carboxylic acid methyl ester as raw material, and one-pot three-site hydrogenation reduction of an olefinic bond and a carbonyl group is simultaneously carried out under the reduction condition of a metal catalyst to obtain a 5beta-hydrogen-7alpha-hydroxyl intermediate with high selectivity, and then chenodeoxycholic acid is obtained through hydrolysis. The method for preparing chenodeoxycholic acid directly constructs two chiral centers (5beta and 7alpha) through one-step hydrogenation. The reaction has the characteristics of simplicity, high efficiency, safe operation, high stereoselectivity and convenient product purification, can effectively prepare chenodeoxycholic acid, and is suitable for industrialization. The application has wide application prospect.

The invention relates to the technical field of biology, and particularly discloses combined application of chenodeoxycholic acid and an anti-PD-1 inhibitor in cancer resistance. The research finds that the anti-tumor effect can be effectively improved through combined use of chenodeoxycholic acid and an anti-PD-1 inhibitor, and then the application of the combined use of the chenodeoxycholic acid compound and the anti-PD-1 inhibitor in preparation of drugs for treating cancers is provided, the chenodeoxycholic acid compound is chenodeoxycholic acid or pharmaceutically acceptable salt, prodrug and metabolite of chenodeoxycholic acid; in a unit preparation of the medicine, the mass ratio of the chenodeoxycholic acid compound to the anti-PD-1 inhibitor is (2.9-26): 1 on the basis of the mass of the chenodeoxycholic acid and the anti-PD-1 inhibitor. According to the method, the anti-tumor effect can be improved, the drug dosage is reduced, the toxic and side effects are reduced, the occurrence of drug resistance is reduced, and an effective new method is provided for tumor treatment.

The invention relates to the technical field of biological medicine chemical separation, and discloses a separation and purification process of high-purity ursodesoxycholic acid mother liquor, which comprises the following steps: adding alkaline amino acid into the mother liquor containing ursodesoxycholic acid, stirring and dissolving to obtain a water phase system; adding a neutral chiral hydrophobic deep-eutectic solvent formed by complexing L-menthol and long-chain fatty alcohol into the water-phase system, and carrying out mixed extraction; standing for layering, separating to remove an upper-layer oil phase, and collecting a lower-layer water phase; finally, acid is added into the water phase to adjust the pH value, and an ursodesoxycholic acid product is obtained through ultrasonic-assisted crystallization, cleaning and drying. According to the method disclosed by the invention, efficient separation of a target product from chenodeoxycholic acid and lithocholic acid is realized by utilizing the specific hydrophilic anchoring effect of the basic amino acid on ursodeoxycholic acid and cooperating with the chiral hydrophobic recognition effect of the eutectic solvent on impurities. The process is green and environment-friendly, the solvent can be recycled, and the obtained product is high in purity and suitable for industrial application.

This invention discloses the application of *Gastrococcus xanthophylloides* in regulating intestinal bile acid metabolism disorders, including *Gastrococcus xanthophylloides* (… Ruminococcus flavefaciens The application of this invention in the preparation of compositions for regulating intestinal bile acid metabolism disorders, wherein the compositions promote the conversion of primary bile acids to secondary bile acids, wherein the primary bile acids include cholic acid and chenodeoxycholic acid, and the secondary bile acids include deoxycholic acid and lithocholic acid; wherein the intestinal bile acid metabolism disorders include metabolic disorders caused by antibiotics, wherein the antibiotics include one or more of moxifloxacin and metronidazole; wherein the compositions can be health products, pharmaceuticals, or feed; and wherein the active ingredient of the compositions includes xanthospirococcus flavus.

The invention discloses a preparation method of high-purity ursodesoxycholic acid, and belongs to the technical field of biological medicines. The method provided by the invention specifically comprises the following steps: carrying out a catalytic oxidation reaction on chenodeoxycholic acid by using 7 alpha-hydroxysteroid dehydrogenase to generate a 7-ketolithocholic acid intermediate, and then carrying out a catalytic reduction reaction on 7 beta-hydroxysteroid dehydrogenase to generate a crude ursodeoxycholic acid product. Further, the crude ursodesoxycholic acid reacts with a triethylamine reagent to generate ursodesoxycholic acid triethylamine salt, and a part of cell impurities are removed; dropwise adding an acid reagent to hydrolyze ursodesoxycholic acid triethylamine salt; and finally, recrystallizing and refining by using ethyl acetate and ethanol to obtain high-purity ursodesoxycholic acid. The method is simple in process and low in cost, the obtained product is high in purity, few organic reagents are used, environmental pollution is little, and industrial production can be achieved.

The application provides a dog and cat tear mark improvement composition containing bile acid and Bifidobacterium animalis subsp. lactis, the composition containing bile acid and Bifidobacterium animalis subsp. lactis ZYhyy-017; the Bifidobacterium animalis subsp. lactis ZYhyy-017 is preserved in the China General Microbiological Culture Collection Center, and the preservation number is CGMCC No. 37292, and the preservation date is January 6, 2026; the bile acid is chenodeoxycholic acid (CDCA). The composition targets the regulation of the bile acid-porphyrin metabolic pathway through the synergistic effect of bile acid and Bifidobacterium animalis subsp. lactis ZYhyy-017, adjusts the porphyrin metabolism in pets from the root, optimizes the intestinal-liver axis metabolism and liver function, realizes the long-term and safe improvement of dog and cat tear marks, fills the technical blank of the application of bile acid and specific probiotics in the field of dog and cat tear mark improvement, and meets the actual needs of pet feeding in tear mark root improvement.

Disclosed in the present invention are a kit for detecting 15 bile acid profiles and three bile acid precursors in serum simultaneously and a detection method therefor. The 15 bile acid profiles comprise: cholic acid, deoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid, lithocholic acid, glycocholic acid, glycodeoxycholic acid, glycochenodeoxycholic acid, glycoursodeoxycholic acid, glycolithocholic acid, taurocholic acid, taurodeoxycholic acid, taurochenodeoxycholic acid, tauroursodeoxycholic acid and taurolithocholic acid; and the three bile acid precursors comprise: 3α,7α-dihydroxycoprostanic acid, 3α,7α,12α-trihydroxycholestanoic acid and 7α-hydroxy-4-cholesten-3-one. The kit and detection method of the present invention enable the simultaneous and accurate detection of the 15 bile acid profiles and the three bile acid precursors, with a short detection time and a high detection accuracy. This, to a certain extent, meets the clinical need for assessing the enterohepatic cycle composed of the biliary system, intestines, portal venous circulation and hepatocytes.

The utility model relates to the technical field of chenodeoxycholic acid crystal production and processing, and discloses a chenodeoxycholic acid concentration and crystallization tank which comprises a shell, the upper surface of the shell is slidably connected with a top cover, the upper surface of the top cover is provided with a filter assembly, the lower surface of the shell is fixedly connected with a temporary storage cover, and the temporary storage cover is provided with a storage cavity. An inner shell is fixedly connected to the interior of the temporary storage cover, a heating wire is fixedly connected to the outer wall of the inner shell, a first support is fixedly connected to the upper surface of the top cover, and a stirring assembly is arranged on the inner wall of the first support; the stirring assembly comprises a motor, the outer wall of the motor is fixedly connected to the inner wall of the first support, and the output end of the motor is fixedly connected with a rotating shaft. According to the chenodeoxycholic acid crystal stirring device, through the shape design of the square stirring blades, crystals attached to the inner wall of the inner shell can be scraped off, the situation that the finally obtained chenodeoxycholic acid crystals are reduced due to the fact that the crystals are attached to the inner wall of the inner shell is avoided, and the production efficiency of the chenodeoxycholic acid crystals is improved.

Methods for stereoselectively crystallizing 3-keto-5β-cholanic acid (“3-KCA”) and 3-ketoursodeoxycholic acid (“3-KUDCA”) of extremely high purity, salts for carrying out such methods, particularly tert-butylamine and cyclohexylamine salts of 3-KCA, tert-butylamine salts of 3-KUDCA, and crystalline forms of these salts, as well as methods for preparing commercial steroid compounds from these purified materials.

A method for preparing a squalamine key intermediate of formula (I), wherein R is as defined in the description. In the method, 5α-chenodeoxycholic acid is used as a raw material, and is reacted with a Weinreb reagent to obtain a Weinreb amide; then, the Weinreb amide is sequentially subjected to an oxidation reaction, a ketalization reaction with ethylene glycol, and a nucleophilic reaction with an organometallic reagent, and is finally subjected to a reductase-catalyzed asymmetric carbonyl reduction reaction to obtain the compound of formula I. The method has the advantages of simple steps, high overall yield, high product purity, etc., and is suitable for industrial production.

Provided are: an FPR1 inhibitor that can be used in a therapeutic agent based on cell death pathology specific to SJS / TEN, and that that can ameliorate the death rate of SJS / TEN; a drug; and a severe drug eruption therapeutic agent. Moreover, provided is an FPR1 inhibitor screening method for seeking these therapeutic agents. The FPR1 inhibitor, the drug, and the severe drug eruption therapeutic agent contain chenodeoxycholic acid or sulfinpyrazone as an active ingredient, and are used for treating severe drug eruption. The FPR1 inhibitor screening method is for seeking these therapeutic agents.

This invention belongs to the field of veterinary pharmacy and relates to the application of chenodeoxycholic acid (CDCA) in the preparation of drugs for treating canine acute pancreatitis. This invention is the first to propose the application of CDCA in the preparation of drugs for treating canine acute pancreatitis, clarifying that it achieves therapeutic effects by reducing pancreatic CT values, alleviating pancreatic edema and necrosis, and improving pancreatic tissue pathological damage, providing a novel strategy and drug option for targeted treatment of canine acute pancreatitis.